Lv3
320 积分 2023-02-20 加入
The therapeutic potential of immunoengineering for systemic autoimmunity
20小时前
待确认
Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial
4个月前
已完结
Ponesimod: First Approval
4个月前
已完结
Ozanimod: First Approval
4个月前
已完结
Siponimod: First Global Approval
4个月前
已完结
Structural insights into sphingosine 1-phosphate receptor 4 activation
4个月前
已完结
The Current Landscape in the Development of Small-molecule Modulators Targeting Sphingosine-1-phosphate Receptors to Treat Neurodegenerative Diseases
4个月前
已完结
Silence of S1PR4 Represses the Activation of Fibroblast-like Synoviocytes by Regulating IL-17/STAT3 Signaling Pathway
4个月前
已完结
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease
4个月前
已完结
Update on ozanimod for ulcerative colitis
5个月前
已完结
皖公网安备34019202002308
